Overview

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

Status:
Not yet recruiting
Trial end date:
2032-06-30
Target enrollment:
Participant gender:
Summary
A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Phase:
Phase 3
Details
Lead Sponsor:
Dendreon